The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Arch Oncology‘s experimental immune-modulating therapy AO-176 as a potential treatment for relapsed or refractory multiple myeloma. This designation, given to therapies with the potential to improve care for conditions that affect fewer than 200,000 people in the U.S., qualifies Arch, as the therapy’s developer, for regulatory support and certain financial incentives. Orphan drugs qualify for seven years of market exclusivity in the…
You must be logged in to read/download the full post.
The post Immune Therapy AO-176 Awarded FDA’s Orphan Drug Designation appeared first on BioNewsFeeds.